Decibel rises on regulatory nod to begin hearing loss therapy trials in UK

Decibel Therapeutics

24/01/2023 17:12

** Shares of gene-therapy developer Decibel Therapeutics
 DBTX.O  up 4% at $2.95
    ** Co announces U.K. approval to begin trials in children
two years of age or younger for its lead candidate, DB-OTO, as a
potential treatment of hereditary hearing loss  urn:newsml:reuters.com:*:nGNX2X6cmc
    ** Decibel intends to initiate the Phase 1/2 clinical trial
of DB-OTO in the first half of 2023, with initial data from the
first cohort of patients in the first quarter of 2024
    ** HC Wainwright sees this as a significant step towards
entering the clinic with IND clearance (for study in humans) in
the U.S., notes Decibel as a potential acquisition target
    ** Last year, stock fell 54.3%
 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((nandhini.srinivasan@thomsonreuters.com))